HB Fuller Company formulates, manufactures and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives and other specialty chemicals worldwide. The company is headquartered in Saint Paul, Minnesota.
| Revenue (TTM) | $3.51B |
| Gross Profit (TTM) | $1.14B |
| EBITDA | $605.88M |
| Operating Margin | 13.30% |
| Return on Equity | 9.39% |
| Return on Assets | 5.05% |
| Revenue/Share (TTM) | $64.33 |
| Book Value | $38.72 |
| Price-to-Book | 1.46 |
| Price-to-Sales (TTM) | 0.88 |
| EV/Revenue | 1.425 |
| EV/EBITDA | 8.95 |
| Quarterly Earnings Growth (YoY) | 61.80% |
| Quarterly Revenue Growth (YoY) | 5.80% |
| Shares Outstanding | $53.79M |
| Float | $53.47M |
| % Insiders | 0.29% |
| % Institutions | 109.32% |
Volatility is currently contracting
Improving demand in major end markets augurs well for The Zacks Chemicals Specialty industry. ESI, FUL, KWR and MTX lean on cost cuts and efficiency moves to offset persistent inflation pressures.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
H. B. Fuller (FUL) reported earnings 30 days ago. What's next for the stock?
Investors interested in Chemical - Specialty stocks are likely familiar with H. B. Fuller (FUL) and Novozymes A/S (NVZMY).
CLDT, PARR, ARCO, CAL and FUL stand out with attractive EV-to-EBITDA ratios and strong earnings outlook.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FUL is tapping medical, aerospace and pricing trends to support margins, but volume weakness still clouds its path to stronger growth.
FUL trades near the low end of its five-year valuation range as improving earnings meet volume, inflation and leverage risks tied to its medical-market expansion.
FUL's outlook rests on pricing, margins and portfolio reshaping as medical expansion and M&A aim to offset uneven demand across key end markets.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FUL and any ticker you trade — then tracks every position and per-strategy win rate.
